Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian Cancer

Video

In Partnership With:

Society for Immunotherapy of Cancer

Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.

Ira Winer, MD, PhD, associate professor, Division of Gynecologic Oncology, Wayne State University, Barbara Ann Karmanos Cancer Institute, discusses the tolerability of ALKS 4230 plus pembrolizumab (Keytruda) in ovarian cancer.

Findings from the ongoing phase 1/2 ARTISTRY-1 trial were presented during the 2020 SITC Virtual Congress.

The results demonstrated objective responses with the combination of ALKS 4230, an investigational engineered cytokine, and pembrolizumab in patients with heavily pretreated, platinum-resistant ovarian cancer.

The ARTISTRY-1 regimen is intensive, but patients appeared to tolerate the combination well, says Winer.

Moreover, the responses appear durable, Winer concludes.

Related Videos
Gottfried Konecny, MD
Patrick I. Borgen, MD
Gottfried E. Konecny, MD, lead clinician, gynecologic oncology, Department of Medicine, the University of California, Los Angeles
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology